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Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has recently been considered as the most public liver 
problem worldwide and a major clinicopathologic health burden in the developed countries. Biochemical tests 
are important in verifying a better understanding of many diseases and hence help to have the right decisions for 
achieving better management.
AIM: This study was conducted to assess biochemical markers in NAFLD Egyptian patients.
METHODS: Forty obese subjects (32 females and 8 males, mean age was 42.32 ± 9.12 years) (20 with NAFLD and 
20 without NAFLD) and 20 normal participants were selected.
RESULTS: Body mass index (BMI) was 40.86 ± 5.45 in obese FL versus 22.07 ± 2.10 in control, p < 0.001 and versus 
35.83 ± 5.94 in obese non-FL, p = 0.003. Alanine aminotransferase (ALT) was 57.30 ± 46.24 in obese FL versus 
25.45 ± 7.12 in control, p = 0.003 and versus 27.35 ± 11.09 in obese non-FL, p = 0.005. Aspartate aminotransferase 
(AST) (41.40 ± 36.09 in obese FL vs. 21.7 ± 3.81 in control, p = 0.015 and vs. 24.05 ± 7.50 in obese non-FL, 
p = 0.032). Total bilirubin (T.Bil) (0.62 ± 0.25 in obese FL vs. 0.47 ± 0.15 in control, p = 0.014). Prothrombin time (PT) 
(86.80 ± 11.32 in obese FL vs. 97.86 ± 4.31 in control, p < 0.001) and International Normalization Ratio (INR) (1.11 
± 0.13 in obese FL vs. 1.01 ± 0.02 in control, p = 0.002). Triglycerides (TGs) (128.20 ± 43.49 in obese FL vs. 88.35 
± 24.26 in control, p < 0.001 and vs. 94.50 ± 31.65 in obese non-FL, p = 0.003). Ferritin (88.21 ± 54.88 in obese FL 
vs. 47.65 ± 32.07 in obese non-FL, p = 0.006). Alpha-fetoprotein (AFP) (2.42 ± 1.67 in obese FL vs. 1.20 ± 0.75 in 
control, p = 0.001). Fasting blood sugar (FBS) (119.70 ± 49.11 in obese FL vs. 84.10 ± 7.19 in control, p < 0.001 and 
vs. 80.50 ± 8.84 in obese non-FL, p < 0.001) and postprandial (P.P) (152.80 ± 82.86 in obese FL vs. 94.35 ± 3.70 in 
control, p < 0.001 and vs. 93.35 ± 7.77 in obese non-FL, p < 0.001). Serum high-density lipoprotein (HDL) level was 
significantly lower in NAFLD patients compared to obese non-FL (40.05 ± 5.81 vs. 41.9 ± 4.85, p < 0.001).
CONCLUSION: NAFLD is associated with changes in biochemical parameters. Its early assessment can help in 
modifying the disease course and delaying complications.
Introduction
Obesity is a state of an excess body fat which 
causes higher risk of metabolic derangements [1]. In 
patients with severe obesity (usually with body mass 
index “BMI” >35 kg/m2), the hepatic steatosis prevalence 
is over 90% from those patients undergoing bariatric 
surgery [2]. Obesity is considered as a tremendous 
threat for health in Egypt. More than one from each 
three Egyptians is obese which is considered among 
the highest rates in the world. According to a recent 
study, 19 million Egyptians are obese, representing 
35% from the total adult population. Moreover, about 
3.6 million children in Egypt are overweight and obese 
representing 10.2% of all Egyptian children [3]. Liver 
steatosis develops when the input rate of hepatic fatty 
acids (synthesis and uptake) is more than the rate of 
output of fatty acids (secretion and oxidation). Obesity 
is considered as one of the non-alcoholic fatty liver 
disease risk factors [4].
NAFLD is a growing and frequent cause for 
chronic liver diseases, influencing about 20–30% from 
the general population worldwide. NAFLD patients, 
particularly those with non-alcoholic steatohepatitis 
(NASH), are at higher risk for progression to cirrhosis 
and its consequent complications, representing a 
higher rate also for cardiovascular diseases and 
cancer compared to those without fatty liver [5]. NAFLD 
includes a broad spectrum of clinicopathologic events 
ranging from simple hepatic steatosis to NASH. Simple 
hepatic steatosis is relatively benign. It is characterized 
by hepatic steatosis in the absence of inflammation or 
fibrosis. The progression into NASH is characterized by 
ballooning of hepatocyte, inflammatory infiltration and 
cellular necrosis that may give rise to complications 
such as liver cirrhosis, hepatocellular carcinoma and 
hepatic failure [6].
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Biochemical tests are very useful for achieving 
a better understanding of the disease and consequently 
allow good management decisions to be made. Liver 
ultrasound examination has relatively high specificity 
(88–95%) and sensitivity (60–95%) [7]. Hence, NAFLD 
diagnosis has been made depending on liver ultrasound 
examination as well as measuring various biochemical 
parameters manifesting hepatic damage or injury. 
Integrating the results into several scores may support 
the diagnosis [8]. Meanwhile, many investigators are 
still searching for simple tools for diagnosis with higher 
specificity and sensitivity that can help as screening 
markers for excessive accumulation of hepatic fat. The 
data elucidate that male prevalence may be recorded 
for NAFLD or an equivalent distribution for gender 
and can be even diagnosed in case of the absence 
of obesity and diabetes. NAFLD may exist at any age 
including the childhood, although the most prevalent is 
found in the age between 40 and 50 years. With some 
restrictions, both hospital-based and population studies 
from Western countries have reported that about 
10–24% of global population in addition to 57–75% of 
obese persons might have NAFLD [9]. Thus, according 
to the mentioned contest, the current study aimed to 
access the association between NAFLD and different 
biochemical parameters, especially liver profile and 
lipid profile in Egyptian population.
Subjects and Methods
Subjects
This study was a case–control study, conducted 
on 40 obese adult subjects aged between 18 and 
65 years, selected from the outpatient clinic attending 
gastrointestinal unit of Nasser Institute Hospital, Cairo, 
Egypt, from September 2016 to September 2017.
They were selected according to the following:
Inclusion criteria
• Obese subjects (BMI > 30 kg/m2) and age 
18–65 years were included in the study.
Exclusion criteria
• Presence of autoimmune hepatitis as detected 
by antinuclear antibody (ANA), presence of 
Wilson disease as detected by ceruloplasmin, 
presence of alpha-1-antitrypsin deficiency 
as detected by alpha-1-antitrypsin assay, 
presence of hepatitis C and B as achieved by 
hepatitis BsAg, hepatitis C antibody, presence 
of iron overload as detected by ferritin, 
presence of hepatocellular carcinoma (HCC) 
as detected by alpha-fetoprotein (AFP), and 
ongoing drug abuse or alcohol abuse.
The 40 patients were divided into two groups 
based on abdominal ultrasound investigation as follows:
Group I: (n = 20) Obese with non-alcoholic 
fatty liver disease (obese FL).
Group II: (n = 20) Obese without non-alcoholic 
fatty liver disease (obese non-FL) with normal liver 
appearance by ultrasound.
Control: (n = 20) Normal weight adult subjects 
(BMI < 25 kg/m2) with normal liver appearance by 
ultrasound.
The study protocol conformed to ethical 
guidelines of the 1975 Declaration of Helsinki, approved 
by the Institutional Review Board (IRB) for Human 
Subject Research at National Hepatology and Tropical 
Medicine Research Institute (NHTMRI), Cairo, Egypt 
(serial: 11-2016). All patients included in this study 
signed an informed consent. All hematological and 
random blood sugar tests were done immediately after 
sample collection.
All patients were subjected to full medical 
history taking, abdominal ultrasound and thorough 
clinical examination including abdominal examination 
with focus on liver examination and anthropometric 
assessment (height [Ht], weight [Wt] and body mass 
index [BMI]).
The following biochemical investigations were 
performed:
Liver function was determined by BECKMAN 
with kits supplied from DADE BEHRING, Germany, 
including direct bilirubin [10], total bilirubin [11], 
alanine aminotransferase (ALT) [12], aspartate 
aminotransferase (AST) [13], alkaline phosphatase 
(ALP) [14], total proteins (TPs) [15], serum albumin 
(ALB) [16], and gamma-glutamyl transpeptidase 
(GGT) [17].
Prothrombin time (PT) and International 
Normalization Ratio (INR) were determined using the 
STAGO compact (USA). Complete blood count (CBC) 
was determined using the Sysmex SE-9000 (Germany). 
Blood glucose was determined according to the method 
of Kunst et al. [18] by the automated device, BECKMAN, 
using kit from DADE BEHRING (Germany).
Hepatitis markers were determined by enzyme-
linked immunosorbent assay (ELISA) 3rd generation 
technique as follows; hepatitis C virus (HCV) by the 
method of Van der Poel et al., [19] (Ortho-Clinical 
Diagnostics [USA]), while hepatitis BsAg was detected 
as described by the method of Thomas [20] (Axiom 
Gesellschaft für Diagnostica und Biochemica mbH 
Company [Germany]). Antinuclear antibody (ANA) was 
detected by enzyme immunoassay (EIA) technique 
according to the method of Tan et al. [21] (Binding 
site Company [UK]). Alpha-fetoprotein (AFP) was 
quantitatively assayed by enzyme immunoassay (EIA) 
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technique according to the method of Uotila et al. [22] 
(Axiom Gesellschaft für Diagnostica und Biochemica 
mbH Company [Germany]). Alpha-1-antitrypsin 
assay was determined by immunoturbidimetric assay 
technique according to the method of Miravitlles 
et al. [23] by cobas c 311/501 (Roche/Hitachi 
cobas c systems [Germany]). Ferritin was quantitatively 
assayed according to the method of White et al. [24] 
(Bios Company [USA]). Ceruloplasmin was determined 
by immunoturbidimetric assay with a kit supplied from 
Roche/Hitachi cobas c systems (Germany) according 
to the method of Kroll et al. [25] by cobas c 311/501.
Lipid profile was determined by Dimension 
with kits supplied from Dimension® clinical chemistry 
system, USA, including total cholesterol (TC) according 
to the method of Rautela et al. [26], triglycerides (TGs) 
according to the method of Rautela et al. [27] and high-
density lipoprotein (HDL-C) according to the method of 
Moshides [28].
Kidney function which was determined by 
BECKMAN with kits supplied from DADE BEHRING, 
Germany, including creatinine according to the method 
of Taussky [29], blood urea nitrogen (BUN) according 
to the method of Talke and Schubert [30], and uric acid 
(UA) as described by Henry [31].
Statistical analysis
Data were statistically analyzed by the 
computerized program “Statistical Package for the 
Social Sciences (SPSS)” software, version “20” for 
Windows. “One-way ANOVA,” ”LSD,” and “Duncan test” 
were used to compare between mean values of the 
analyzed parameters. Data were represented as Mean 
± S.D. Values were considered significant at p ≤ 0.05.
Results
Patients were suspected to have NAFLD (by 
abdominal ultrasound). In addition, 20 age-matched 
non-obese healthy subjects were taken as control 
group with a mean age of 30.15 ± 11.53 years.
According to the results of abdominal ultrasound, 
patients were divided into two subgroups 
(Table 1):
• Group 1: Obese with non-alcoholic fatty liver 
disease (NAFLD); they were 20 patients 
(14 females and 6 males) with mean age 44.96 
± 8.71 years.
• Group 2: Obese without NAFLD; they were 
20 patients (18 females and 2 males) with 
mean age 39.15 ± 8.27 years (Table 1).
There was a highly significant difference when 
compared BMI of the obese FL group with the control 
group with p < 0.001. Furthermore, there was a highly 
significant difference between the obese non-FL group 
and the control group with p < 0.001 and a significant 
difference between the obese FL group and obese 
non-FL group with p = 0.003 (Table 1).
Table 1: Sex and BMI of control, obese FL group, and obese 
non-FL group
Parameter Control Obese FL Obese non-FL
Sex M=12, F=8 M=6, F=14 M=2, F=18
BMI (kg/m2) 22.07 ± 2.10a 40.86 ± 5.45b 35.83 ± 5.94c
One-way ANOVA was used. LSD and Duncan test were used. Data are represented as mean±S.D. Values 
that share different letters in the same row are significant, otherwise are non-significant.
Table 2: Liver profile and coagulation profile of control, obese 
FL group, and obese non-FL group
Parameter Control Obese FL Obese non-FL
T.Bil (mg/dl) 0.47 ± 0.15a 0.62 ± 0.25b 0.55 ± 0.16ab
D.Bil (mg/dl) 0.11 ± 0.04 0.14 ± 0.06 0.13 ± 0.04
ALT (IU/L) 25.45 ± 7.12a 57.30 ± 46.24b 27.35 ± 11.09a
AST (IU/L) 21.70 ± 3.81a 41.40 ± 36.09b 24.05 ± 7.50a
ALP (IU/L) 81.30 ± 20.38 66.65 ± 21.01 83.65 ± 36.41
TP (gm/dl) 7.53 ± 0.59 7.49  ± 0.50 7.33 ± 0.47
ALB (gm/dl) 4.17 ± 0.32a 3.96 ± 0.31b 3.94 ± 0.30b
PT % activity 97.86 ± 4.31a 86.80 ± 11.32b 89.58 ± 6.23b
INR 1.01 ± 0.02a 1.11 ± 0.13b 1.06 ± 0.06ab
One-way ANOVA was used. LSD and Duncan test were used. Data are represented as mean±S.D. Values 
that share different letters in the same row are significant, otherwise are non-significant.
Table 2 shows liver function and coagulation 
profile of all studied groups. A significant difference 
between the control group and the obese FL group for 
the total bilirubin was recorded, while no significant 
differences was noticed among all groups in case of 
direct bilirubin. In respect to liver enzymes ALT and AST, 
there was a significant difference for each of the obese 
FL group compared to the control group (p = 0.003 
and p = 0.015, respectively) and the obese FL group 
compared to the obese non-FL group (p = 0.005 and 
p = 0.032, respectively). On the other hand, ALP showed 
no significant difference among all studied groups. The 
albumin showed a significant difference when comparing 
the obese FL group with the control group and the obese 
non-FL group with the control group (p = 0.046 and 
p = 0.029, respectively), while no significant difference 
was noticed for the total protein among all studied groups. 
Data obtained for PT showed a significant difference 
when comparing the obese FL with the control group and 
the obese non-FL group with the control group (p < 0.001 
and p = 0.004, respectively), while there was a significant 
difference only for the INR between the obese FL and 
control p = 0.002, but no significance between the obese 
non-FL and the control group was noticed.
Kidney profile and blood sugar of all studied 
groups are illustrated in Table 3. There was a significant 
reduction in BUN for the obese FL group compared to 
the control group (p = 0.028), also there was a highly 
significant reduction for the obese non-FL group 
compared to the control group (p = 0.001). The creatinine 
showed a significant increase when comparing the 
obese FL group with the control group or with the obese 
non-FL group (p = 0.028 and p = 0.046, respectively), 
while there was a significant increase only for the UA 
between the obese FL and control p = 0.007, but no 
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significance between the obese non-FL and the control 
group was noticed. In respect to FBS and P.P, there 
was a highly significant increase for each of the obese 
FL group compared to the control group (p < 0.001 
and p < 0.001, respectively) and the obese FL group 
compared to the obese non-FL group (p < 0.001 and p 
< 0.001, respectively).
increase when comparing the obese FL group with the 
control group or with the obese non-FL group (p = 0.003 
and p = 0.010, respectively), while there was a significant 
increase only for the ferritin between the obese FL and 
obese non-FL group (p = 0.006), but no significance 
between the obese FL and the control group was 
noticed. On the other hand, alpha-1-antitrypsin showed 
no significant difference among all studied groups.
Discussion
The present study was conducted to 
investigate the relationship between NAFLD and 
different biochemical parameters, especially liver profile 
and lipid profile in Egyptian population.
The body mass index (BMI) was significantly 
higher in NAFLD cases than in normal control 
participants (p < 0.001). Moreover, BMI was significantly 
lower in obese non-FL group compared to obese FL 
group (p = 0.003). This finding agrees with the results 
obtained by other authors who reported that NAFLD 
has been detected as a complication for the majority 
(>95%) of patients having severe obesity (BMI = 35 
or more) [32], [33]. Yang et al. [34] found that BMI 
was confirmed as the most useful predictive factor 
for NAFLD onset in both sexes in a community-based 
retrospective longitudinal cohort study. On the other 
hand, the previous studies concluded that NAFLD can 
occur in non-obese subjects who are physically inactive 
“Metabolic obesity” [35], [36].
Approximately 80% of patients with 
NAFLD have liver function tests in normal ranges; 
only a small proportion exhibits mild elevation of 
aminotransferases [37]. In the present study, serum 
ALT level was significantly higher in NAFLD cases than 
in normal control participants (p = 0.003) and in obese 
FL group compared to obese non-FL group (p = 0.005). 
This agrees with the previous studies which concluded 
that ALT is more predictive for accumulation of liver 
fat among the liver enzymes and correlates with liver 
fat independent of obesity and can be an independent 
predictor of the inflammation degree [38], [39], [40]. 
Elevation of liver enzymes, particularly ALT, is often the 
first sign for NAFLD; about 1–3 times increase of its 
normal level being reported [41].
Serum AST level was significantly higher 
in obese FL group compared to normal control 
Table 3: Kidney profile and blood sugar of control, obese FL 
group, and obese non-FL group
Parameter Control Obese FL Obese non-FL
BUN (mg/dl) 13.95 ± 4.02a 11.72 ± 2.07b 10.55 ± 2.98b
Creat (mg/dl) 0.68 ± 0.15a 0.80 ± 0.22b 0.69 ± 0.16a
UA (mg/dl) 3.59 ± 1.33a 4.73 ± 1.27b 4.15 ± 1.26ab
FBS (mg/dl) 84.10 ± 7.19a 119.70 ± 49.11b 80.50 ± 8.84a
P.P (mg/dl) 94.35 ± 3.70a 152.80 ± 82.86b 93.35 ± 7.77a
One-way ANOVA was used. LSD and Duncan test were used. Data are represented as mean±S.D. Values 
that share different letters in the same row are significant, otherwise are non-significant.
Table 4: Lipid profile of control, obese FL group, and obese 
non-FL group
Parameter Control Obese FL Obese non-FL
TC (mg/dl) 178.85 ± 27.90 176.90 ± 41.79 170.90 ± 49.16
TG (mg/dl) 88.35 ± 24.26a 128.20 ± 43.49b 94.50 ± 31.65a
HDL-C (mg/dl) 41.90 ± 4.85ab 40.05 ± 5.81a 45.16 ± 9.15b
One-way ANOVA was used. LSD and Duncan test were used. Data are represented as mean±S.D. Values 
that share different letters in the same row are significant, otherwise are non-significant.
Table 4 shows lipid profile of all studied groups. 
The TG showed a highly significant increase when 
comparing the obese FL group with the control group or 
with the obese non-FL group (p < 0.001 and p = 0.003, 
respectively), while there was a significant increase 
only for the HDL-C between the obese FL and obese 
non-FL groups (p = 0.022), but no significance between 
the obese non-FL and the control group was noticed. 
On the other hand, total cholesterol (TC) showed no 
significant difference among all studied groups.
Table 5 shows blood picture of all studied 
groups. There was a significant difference in RBCs for 
the obese non-FL group compared to the control group 
(p = 0.012), while no significant difference was noticed 
for the RBCs when comparing obese FL group to the 
control group. On the other hand, WBCs, Hb, and Plt 
showed no significant difference among all studied 
groups.
Table 5: Blood picture of control, obese FL group, and obese 
non-FL group
Parameter Control Obese FL Obese non-FL
WBCs (103/µl) 6.53 ± 1.82 7.62 ± 2.07 6.45 ± 2.38
RBCs (106/µl) 5.07 ± 0.53a 4.84 ± 0.65ab 4.64 ± 0.38b
Hb g/dl 13.36 ± 1.94 13.01 ± 1.55 12.59 ± 0.99
Plt (103/µl) 259.25 ± 51.66 289.65 ± 67.90 274.40 ± 62.56
WBCs: White blood cells, RBCs: Red blood cells, Hb: Hemoglobin. One-way ANOVA was used. LSD and 
Duncan test were used. Data are represented as mean ± S.D. Values that share different letters in the 
same row are significant, otherwise are non-significant.
Table 6: AFP, ceruloplasmin, alpha-1-antitrypsin, and ferritin 
of control, obese FL group, and obese non-FL group
Parameter Control Obese FL Obese non-FL
AFP (ng/ml) 1.20 ± 0.75a 2.42  ± 1.67b 1.77 ± 0.69ab
Ceruloplasmin (mg/dl) 33.60 ± 6.99a 42.35 ± 9.98b 34.70 ± 9.83a
Alpha-1-antitrypsin (mg/dl) 131.20 ± 15.25 134.25 ± 19.06 134.00 ± 25.31
Ferritin (ng/dl) 67.14 ± 45.32ab 88.21 ± 54.88a 47.65 ± 32.07b
AFP: Alpha-fetoprotein. One-way ANOVA was used. LSD and Duncan test were used. Data are 
represented as mean ± S.D. Values that share different letters in the same row are significant, otherwise 
are non-significant
AFP, ceruloplasmin, alpha-1-antitrypsin, and 
ferritin of all studied groups are illustrated in Table 6. 
There was a highly significant difference in AFP for 
the obese FL group compared to the control group 
(p = 0.001), while no significant difference was noticed 
for the AFP when compared obese non-FL group to the 
control group. The ceruloplasmin showed a significant 
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participants (p = 0.015) and in obese FL group 
compared to obese non-FL group (p = 0.032). This 
agrees with the previous studies which found that AST 
was independently associated with NAFLD and can 
be considered as an independent marker for hepatic 
fibrosis severity [40], [42], [43].
This study showed that serum T.Bil level was 
significantly higher in obese FL group than in normal 
control participants (p = 0.014), while there was no 
significant change in serum T.Bil level between obese 
FL group and obese non-FL group (p = 0.226). Data 
obtained in the present study can be interpreted either 
as an undiagnosed Gilbert’s disease or as a response 
to combat NASH by the protective antioxidant role of 
bilirubin [44]. Tian et al. [45] reported that elevated 
levels of serum bilirubin are inversely associated 
with NAFLD which was explained on the basis of 
the antioxidant effect of bilirubin. Serum bilirubin, the 
end product of haem metabolism, has been found to 
possess potential antagonizing oxidative stress and 
inflammatory properties by acting as antioxidant and 
cytoprotectant in vitro and in vivo. Meanwhile, NAFLD 
is frequently demonstrated to strikingly associate with 
the risk of metabolic syndrome, type 2 diabetes, and 
cardiovascular diseases independent of other classical 
risk factors [20], [21], [22]. Therefore, a straightforward 
hypothesis has been proposed that bilirubin may 
contribute to protection against NAFLD risk, probably 
based on the antioxidant effects of bilirubin.
The serum albumin in this  study although in the 
normal range, it was significantly lower in NAFLD cases 
when being compared to normal control (p = 0.046). 
It seems that the obtained results for albumin are in 
accordance with Hadizadeh et al. [44] who reported that 
albumin was said to be a factor related to steatohepatitis 
and as a predictor for hepatic-related mortality.
In the present study, plasma PT level was 
significantly lower in obese FL group compared to 
normal control participants (p < 0.001) and INR ratio 
was significantly higher in obese FL group compared to 
normal control participants (p = 0.002), but they are still 
in the normal range. This agrees with Saremi et al. [46] 
who found that PT and PTT (partial thromboplastin 
time) have a negative association with NAFLD.
Serum FBS level was significantly higher when 
either comparing obese FL group to normal control 
participants (p < 0.001) or to obese non-FL group 
(p < 0.001). In addition, serum P.P glucose level was 
significantly higher in obese FL group when compared 
to either normal control participants (p < 0.001) or to 
obese non-FL group (p < 0.001). Macherla [47] reported 
similar results. Furthermore, Saini et al. [48] found that 
HbA1C and FBS levels in NAFLD patients were found 
to be significantly higher compared to the control group. 
It has been shown that excess deposition of fat in liver 
(NAFLD) has powerful cross-sectional associations with 
insulin resistance, obesity, and T2DM. Pang et al. [49] 
found that there is a higher NAFLD prevalence in 
pre-diabetic individuals as well as overt T2DM.
The level of serum TG was significantly 
higher in obese FL group compared to normal control 
participants (p < 0.001) or to obese non-FL group 
(p = 0.003), while serum HDL-C level was significantly 
lower in obese FL group compared to obese non-FL 
group (p = 0.022). It was reported that low levels of 
HDL-C and high levels of TGs are among the most 
important criteria of NAFLD patients [34]. The obtained 
results for TGs and HDL-C in the present study are in 
agreement with other studies [50], [51].
Serum creatinine and UA levels were 
significantly higher in obese FL group compared to 
normal control participants (p = 0.028 and 0.007, 
respectively), even they are in the normal range. 
Only serum creatinine level was significantly higher 
in obese FL group compared to obese non-FL group 
(p = 0.046). On the other hand, there was a significant 
decrease in serum BUN level when comparing obese 
FL group to the control group (p = 0.028). This agrees 
with Darmawan et al. [52] who stated that higher 
levels of serum UA are independently and positively 
associated with the presence of hepatic steatosis. 
Moreover, he added that serum UA within the normal 
range correlated positively with tumor necrosis factor-α 
(TNF-α), interleukin-18 (IL-18), and IL-6. It also induced 
oxidative stress in vascular cells and adipocytes. UA 
increases the lipogenic effects of fructose by increasing 
the expression of ketohexokinase (KHK) that resulted 
in accumulation of TGs in hepatocytes. Furthermore, 
Feng et al. [53] mentioned that NAFLD patients had 
elevated levels of renal function parameters (BUN, 
creat, and UA) compared to control participants, even if 
they are within the normal ranges.
The obtained results of serum AFP level 
were significantly higher in NAFLD cases compared 
to normal control participants (p = 0.001), even if it is 
still in the normal range. These results were  similar 
to other studies Babali et al. [54], Xu et al. [55] who 
observed that serum AFP levels are significantly 
raised in NAFLD patients and that levels of AFP are 
significantly associated with metabolic parameters. 
Univariate logistic analysis showed that increased 
levels of serum AFP are associated with an increased 
NAFLD risk. However, multivariate logistic regression 
analysis revealed that AFP is not associated 
independently with the NAFLD risk factors. The study 
suggested a significant association between NAFLD 
and AFP. They finally said that AFP acts as a cofactor 
for NAFLD, but not as an independent factor. The 
mechanism by which AFP increases may be as a result 
of ongoing inflammation, most probably secondary to 
cellular destruction or stimulation of AFP production by 
cytokines. Elevated serum AFP levels may also be due 
to altered hepatocyte-hepatocyte interaction and the 
loss of normal architectural arrangements.
Serum ceruloplasmin (CP) level was 
significantly higher in obese FL group compared to 
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normal control participants (p = 0.003), although it 
was still in the normal range. Furthermore, serum 
ceruloplasmin level was significantly higher in obese FL 
group compared to obese non-FL group (p = 0.010). 
This finding is in agreement with the study of Xu 
et al. [56]. In addition, it is well known that CP is an 
acute-phase reactant, and CP levels in the blood 
plasma increase when the immune system responds 
to infection and inflammation. Inflammatory responses 
are largely mediated by cytokines. Patients with acute, 
subacute, and chronic liver failure had the lowest mean 
serum CP. However, data obtained in the present study 
can be interpreted on the basis that the studied patients 
were still in a degree of liver inflammation and did not 
reach the degree of liver failure.
Serum ferritin level was non-significantly 
higher in obese FL group compared to normal control 
participants. However, serum ferritin level was 
significantly higher in obese FL group compared to 
obese non-FL group (p = 0.006). This agrees with Du 
et al. [57]. Furthermore, Barros et al. [58] added that 
serum ferritin can be considered as a non-invasive 
prognostic marker for NAFLD patients.
Conclusion
The present study revealed an altered liver 
function and lipid profile in cases of NAFLD. Altered 
values for the above biochemical parameters may play 
a crucial role in monitoring the disease progression 
and severity. Early detection could support not only in 
modifying the course of the disease but delaying any 
further complications as well. Recently, various serum 
biomarkers and laboratory tests have been proposed 
as surrogates of liver histology. Notably, non-invasive 
serum biomarkers, when combined, may reduce the 
number of liver biopsies needed for correctly classifying 
hepatic steatosis.
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